Saxenda is a slimming tool. Buy Saxenda for weight loss because it is for people who are severely overweight or obese. With the component liraglutide as the active ingredient, this medicine will stimulate the pancreas to produce insulin. You will feel full for longer and your blood sugar will be under control. It is generally prescribed for people with a body mass index (BMI) of 27 kg / m2 or more. Obesity should not be neglected, as it can be dangerous by increasing the risk of diabetes, cardiovascular disease, and high blood pressure. In addition to those health hazards, being overweight can also bring unwanted effects, such as additional stress on the joints and shortness of breath. By losing weight, you will reduce these health risks and improve your overall health.
|Treatment||Dosage||Quantity||Per Pill||Price||Buy now|
Lose weight with Saxenda because clinical trials are conducted under highly variable conditions, the rates of adverse reactions seen in clinical trials of one drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates seen in the drug practice.
The safety of Saxenda was evaluated in 5 double-blind, placebo-controlled trials involving 3384 overweight or obese patients treated with Saxenda for a treatment period of up to 56 weeks (3 trials), 52 weeks (1 trial), and 32 weeks (1 ) judgment). All patients received study drug in addition to advice on diet and exercise. In these trials, patients received Saxenda for a mean treatment duration of 45.9 weeks (median, 55.9 weeks). Of these, 1087 Saxenda-treated patients and 497 placebo-treated patients have been exposed in their original randomized groups beyond the primary endpoint for an additional mean duration of 53.0 weeks (median, 56.9 weeks). Baseline characteristics included a mean age of 47 years, 71% female, 85% white, 39% with hypertension, 15% with type 2 diabetes, 34% with dyslipidemia, 29% with a BMI greater than 40 kg / m², and 9 % with cardiovascular disease. The dose was started and increased weekly to reach the 3 mg dose.
In clinical trials, 9.8% of Saxenda-treated patients and 4.3% of placebo-treated patients discontinued treatment prematurely as a result of adverse reactions. The most common adverse reactions leading to discontinuation were nausea (2.9% versus 0.2% for Saxenda and placebo, respectively), vomiting (1.7% versus less than 0.1%), and diarrhea (1.4% versus 0%).
Buy Saxenda which can lower blood glucose. In a clinical trial involving patients with type 2 diabetes mellitus who were overweight or obese, severe hypoglycemia (defined as the assistance of another person) occurred in 3 (0.7%) of 422 patients treated with Saxenda and in none of all 212 treated with placebo. patients Each of these 3 patients treated with Saxenda was also taking a sulphonylurea. In the same trial, among patients taking a sulfonylurea, documented symptomatic hypoglycemia (defined as documented symptoms of hypoglycemia in combination with plasma glucose less than or equal to 70 mg / dL) occurred in 48 (43.6%) of 110 patients. Saxenda-treated and 15 (27.3%) of 55 placebo-treated patients. Sulfonylurea doses were reduced by 50% at the start of the per-protocol trial. The frequency of hypoglycemia may be higher if the dose of sulfonylurea is not reduced. Among patients not taking a sulphonylurea, documented symptomatic hypoglycemia occurred in 49 (15.7%) of 312 Saxenda-treated patients and 12 (7.6%) of 157 placebo-treated patients. Buy Saxenda UK which is easily available.
In clinical trials of Saxenda with patients without type 2 diabetes mellitus, there was no routine capture or reporting of hypoglycemia, as patients did not receive blood glucose meters or hypoglycemia diaries. 46 (1.6%) of 2,962 Saxenda-treated patients and 19 (1.1%) of 1,729 placebo-treated patients reported spontaneous symptomatic episodes of unconfirmed hypoglycemia. Fasting plasma glucose values obtained at routine clinic visits less than or equal to 70 mg / dL, regardless of hypoglycemic symptoms, were reported as "hypoglycemia" in 92 (3.1%) patients treated with Saxenda and 13 (0.8%) patients treated with placebo. Buy Saxenda online to explore more.
In clinical trials, approximately 68% of Saxenda-treated patients and 39% of placebo-treated patients reported gastrointestinal disturbances; The most frequent was nausea (39% and 14% of patients treated with Saxenda and placebo, respectively). The percentage of patients reporting nausea decreased as treatment continued. Other common adverse reactions that occurred with a higher incidence among Saxenda-treated patients included diarrhea, constipation, vomiting, dyspepsia, abdominal pain, dry mouth, gastritis, gastroesophageal reflux disease, flatulence, belching, and abdominal distention. Most episodes of gastrointestinal events were mild or moderate and did not lead to discontinuation of therapy (6.2% with Saxenda versus 0.8% with placebo discontinued treatment as a result of gastrointestinal adverse reactions).
Patients treated with Saxenda may develop anti-liraglutide antibodies. Anti-liraglutide antibodies were detected in 42 (2.8%) of 1505 Saxenda-treated patients with a post-baseline evaluation. Antibodies that had a neutralizing effect on liraglutide in an in vitro assay occurred in 18 (1.2%) of 1505 patients treated with Saxenda. The presence of antibodies may be associated with an increased incidence of injection site reactions and reports of low blood glucose levels. In clinical trials, these events were generally classified as mild and resolved as patients continued treatment.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. In addition, the observed incidence of antibody positivity (including neutralizing antibody) in an assay can be influenced by several factors, including assay methodology, sample handling, the timing of sample collection, concomitant medications, and the underlying disease. For these reasons, the incidence of antibodies to Saxenda cannot be directly compared with the incidence of antibodies to other products.
Urticaria was reported in 0.7% of Saxenda-treated patients and 0.5% of placebo-treated patients. Anaphylactic reactions, asthma, bronchial hyperresponsiveness, bronchospasm, oropharyngeal swelling, facial swelling, angioedema, pharyngeal edema, type IV hypersensitivity reactions have been reported in patients treated with liraglutide in clinical trials. Anaphylactic reactions with additional symptoms such as hypotension, palpitations, dyspnoea, and edema have been reported with the commercial use of liraglutide. Anaphylactic reactions can be life-threatening.
Injection site reactions were reported in approximately 13.9% of Saxenda-treated patients and 10.5% of placebo-treated patients. The most common reactions, each reported by 1% to 2.5% of Saxenda-treated patients and more commonly than placebo-treated patients, included erythema, itching, and injection site rash. 0.6% of Saxenda-treated patients and 0.5% of placebo-treated patients discontinued treatment due to injection site reactions.
In Saxenda clinical trials, adjudication-confirmed breast cancer was reported in 14 (0.6%) of 2,379 women treated with Saxenda compared with 3 (0.2%) of 1,300 women treated with placebo, including cancer invasive (11 women treated with Saxenda and 2 women treated with placebo) and ductal carcinoma in situ (3 women treated with saxenda and 1 treated with placebo). Most of the cancers were estrogen and progesterone receptor positive. There were too few cases to determine if these cases were related to Saxenda. Furthermore, there are insufficient data to determine whether Saxenda has an effect on pre-existing breast neoplasia.
In Saxenda clinical trials, adjudication-confirmed papillary thyroid carcinoma was reported in 7 (0.2%) of 3,291 Saxenda-treated patients compared with no cases among 1,843 placebo-treated patients. Four of these papillary thyroid carcinomas were less than 1 cm in diameter and 4 were diagnosed in surgical pathology specimens after thyroidectomy elicited by findings identified before treatment.
In Saxenda clinical trials, adjudication confirmed benign colorectal neoplasms (mostly colon adenomas) were reported in 17 (0.5%) of 3,291 patients treated with Saxenda compared with 4 (0.2%) of 1,843 patients treated with placebo. Two positively adjudicated cases of malignant colorectal carcinoma were reported in Saxenda-treated patients (0.1%) and none in placebo-treated patients.
In the Saxenda clinical trials, 11 (0.3%) of 3384 Saxenda-treated patients compared with none of the 1941 placebo-treated patients had a cardiac conduction disorder, reported as first-degree atrioventricular block, right bundle branch block, or left bundle branch block.
Hypotension-related adverse reactions (i.e., reports of hypotension, orthostatic hypotension, circulatory collapse, and decreased blood pressure) were reported more frequently with Saxenda (1.1%) compared to placebo (0.5%). in Saxenda clinical trials. Systolic blood pressure decreases to less than 80 mmHg were observed in 4 (0.1%) patients treated with Saxenda compared to no patients treated with placebo. One of the patients treated with Saxenda had hypotension associated with gastrointestinal adverse reactions and renal failure.
Increases in alanine aminotransferase (ALT) greater than or equal to 10 times the upper limit of normal were observed in 5 (0.15%) patients treated with Saxenda (two of whom had ALT greater than 20 and 40 times the upper limit than normal) compared to 1 (0.05%) patient treated with placebo during Saxenda clinical trials. Since clinical evaluation to exclude alternative causes of ALT and aspartate aminotransferase (AST) elevations was not performed in most cases, the relationship with Saxenda is uncertain. Some increases in ALT and AST were associated with other confounders (such as gallstones).
Calcitonin, a biomarker for TCM, was measured throughout the clinical development program [see WARNINGS AND PRECAUTIONS]. More patients treated with Saxenda in clinical trials were found to have high calcitonin values during treatment, compared to placebo. The proportion of patients with calcitonin greater than or equal to 2 times the upper limit of normal at the end of the trial was 1.2% in patients treated with Saxenda and 0.6% in patients treated with placebo. Calcitonin values greater than 20 ng / L at the end of the trial occurred in 0.5% of Saxenda-treated patients and 0.2% of placebo-treated patients; Among patients with pretreatment serum calcitonin less than 20 ng / L, none had calcitonin elevations greater than 50 ng / L at the end of the trial.
Serum lipase and amylase were routinely measured in Saxenda clinical trials. Among patients treated with Saxenda, 2.1% had a lipase value at any time during treatment of more than or equal to 3 times the upper limit of normal compared with 1.0% of patients treated with placebo. 0.1% of Saxenda-treated patients had an amylase value at any time in the trial of more than or equal to 3 times the upper limit of normal versus 0.1% of placebo-treated patients. The clinical significance of elevations in lipase or amylase with Saxenda in the absence of other signs and symptoms of pancreatitis is unknown.Buy Saxenda With an Online Prescription and get to know more about it.